Transaction DateRecipientSharesTypePriceValue
16th October 2020Charles J Homcy10,256Exercise of derivative$17.00$174,352.00
16th October 2020Charles J Homcy10,256Open or private sale$41.00$420,496.00
12th October 2020Mardi Dier40,000Grant/award etc.$0.00
30th September 2020Charles J Homcy10,000Exercise of derivative$17.00$170,000.00
30th September 2020Charles J Homcy10,000Open or private sale$38.00$380,000.00
29th September 2020Mardi Dier10,000Open or private purchase$19.00$190,000.00
29th September 2020Charles J Homcy18,200Open or private sale$37.50$682,500.00
25th September 2020Charles J Homcy65,661Open or private sale$36.68$2,408,589.93
25th September 2020Charles J Homcy15,396Open or private sale$37.47$576,865.03
17th August 2020Ted W Love1,799Grant/award etc.$0.00
Portola Pharmaceuticals
Portola Pharmaceuticals logo

Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics. It offers Andexxa, and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003.

Ticker: PTLA
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1269021
Employees: 408
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $196 M (0%)
Inventory, Net: $4 M (0%)
Assets, Current: $392 M (-15%)
Property, Plant and Equipment, Net: $5 M (14%)
Assets: $513 M (-11%)
Long-term Debt, Current Maturities: $9 M (-54%)
Accounts Payable, Current: $13 M (5%)
Liabilities, Current: $80 M (-21%)
Other Liabilities, Noncurrent: $7 M (81%)
Liabilities: $441 M (-1%)
Common Stock, Value, Issued: $80 Th (0%)
Common Stock, Shares, Issued: $78 M (0%)
Retained Earnings (Accumulated Deficit): $2 B (3%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $828 Th (2265%)
Liabilities and Equity: $513 M (-11%)
Revenue: $26 M (0%)
Cost of Revenue: $4 M (-39%)
Research and Development: $26 M (-26%)
Operating Income/Loss: $58 M (-20%)
Other Income, net: $2 M (10%)